Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial

INTRODUCTION: Complement 3 glomerulopathy (C3G) is a rare kidney disease characterized by dysregulation of the alternative pathway (AP) of the complement system. About 50% of patients with C3G progress to kidney failure within 10 years of diagnosis. Currently, there are no approved therapeutic agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Bomback, Andrew S., Kavanagh, David, Vivarelli, Marina, Meier, Matthias, Wang, Yaqin, Webb, Nicholas J.A., Trapani, Angelo J., Smith, Richard J.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546729/
https://www.ncbi.nlm.nih.gov/pubmed/36217526
http://dx.doi.org/10.1016/j.ekir.2022.07.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546729/
https://www.ncbi.nlm.nih.gov/pubmed/36217526
http://dx.doi.org/10.1016/j.ekir.2022.07.004

Ejemplares similares